2015 Congress

Abstracts
Webcasts
Scientific Posters
Industry sessions
Final Programme

Abstracts


The abstracts from this meeting are published as a supplement to the Journal of Viral Hepatitis. The supplement is available online here.

Webcasts


Thursday 10 September

Welcome and introduction
Ira Jacobson, New York, US and Stefan Zeuzem, Frankfurt, Germany Click here to view 

Keynote lecture
HCV registries: what have we learned beyond the phase III trials?
David Nelson, Gainsville, US – Click here to view

Hepatitis C: where are we now? The landscape
US vs. EU: differences in the labels and guidelines for anti-HCV regimens
Nezam Afdhal, Boston, US – Click here to view

Which DAA regimen should include ribavirin?
Graham Foster, London, UK – Click here to view 

Drug–drug interactions: what remains relevant in HCV treatment?
David Back, Liverpool, UK – Click here to view

Q&A and discussion – Click here to view

New data from latest clinical trials
Real-life results of triple therapy with the combination of sofosbuvir-pegylated
interferon-ribavirin for Egyptian patients with hepatitis C 
Gamal Esmat, Cairo, Egypt – Click here to view

Efficacy and safety of paritaprevir/r/ombitasvir/dasabuvir ± ribavirin in genotype 1 HCV
infected patients treated in real life settings (AMBER study)
Robert Flisiak, Bialystok, Poland – Click here to view

Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients
with severe liver disease: interim results of a compassionate use program
Tania Welzel, Frankfurt, Germany – Click here to view

Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and
post liver transplantation patients with HCV infection: preliminary results of
the prospective SOLAR 2 trial
Didier Samuel, Villejuif, France – Click here to view

HCV-infected patients with renal and/or hepatic impairment
and post-transplant
Treatment of patients with pre-terminal and terminal renal insufficiency
Paul Martin, Miami, US – Click here to view

Treatment of patients with decompensated liver cirrhosis: who benefits, who deteriorates,
where is the point of no return?
Marc Bourlière, Marseille, France – Click here to view

Anti-viral management post-liver transplantation
Paul Kwo, Indianapolis, US – Click here to view

Friday 11 September

Keynote lecture
The chronic liver failure–sequential organ failure assessment score (CLIF-SOFA) and its
impact on clinical management
Vicente Arroyo, Barcelona, Spain – Click here to view

Viral hepatitis B and D: preclinical and early clinical
What have we learned since the identification of the HBV entry receptor NTCP?
Stephan Urban, Heidelberg, Germany – Click here to view

New drug targets for HBV and clinical data from phase I/II studies
Amir Shlomai, Petah Tikva, Israel – Click here to view

HDV replication and putative drug targets
Heiner Wedemeyer, Hannover, Germany – Click here to view

Q&A and discussion  – Click here to view

Case and panel discussion
HIV/HCV co-infection
Jürgen Rockstroh, Bonn, Germany – Click here to view

Patients with genotype 3 (advanced fibrosis)
Michael Fried, Chapel Hill, US – Click here to view

Genotype 4
Maria Buti, Barcelona, Spain – Click here to view

NAFLD, NASH, NASH cirrhosis
Who gets NASH and what are the health-risks?
Vlad Ratziu, Paris, France – Click here to view

The Current and Future Medical Treatment of NASH: From Vitamin E to
Farnesoid X Receptor (FXR) agonists
Zobair Younossi, Falls Church, US – Click here to view

Which treatments and endpoints for NASH trials are clinically relevant?
Detlef Schuppan, Mainz, Germany – Click here to view

Complications of liver cirrhosis: management
Which drugs should be used to treat diabetes in cirrhotic patients?
Jörg Bojunga, Frankfurt, Germany – Click to view PDF slides only

Treatment algorithm for portal and mesenteric vein thrombosis in cirrhosis
Martin Rössle, Freiburg, Germany – Click here to view

Management of severe ascites: intraperitoneal alfa pump vs TIPS
Rajiv Jalan, London, UK – Click here to view

Saturday 12 September

Hepatocellular carcinoma
HCC surveillance in patients who regressed from cirrhosis
Massimo Colombo, Milan, Italy – Click here to view

Transarterial chemoembolisation: what is the best protocol? TACE + RFA vs TACE
Jean-Francois Dufour, Bern, Switzerland – Click here to view

Which patients can be considered for SIRT
Markus Peck-Radosavljevic, Vienna, Austria – Click here to view

HBV clinical 
When and in whom to stop nuc therapy?
Harry Janssen, Toronto, Canada – Click here to view

Combination therapy: interferon and nucs
Tarik Asselah, Clichy, France – Click here to view

Nephroprotective role of telbuvidine: when is it clinically relevant?
George Papatheodoridis, Athens, Greece – Click here to view

Q&A and discussion – Click here to view

Future of HCV treatment
Resistance-associated variants and HCV chimera: to what extent do they matter?
Christoph Sarrazin, Frankfurt, Germany – Click here to view

Treatment options in patients who have failed DAA regimens
Mark Sulkowski, Baltimore, US – Click here to view

Which anti-HCV drugs will be approved after the VHC 2015?
Jordan Feld, Toronto, Canada – Click here to view

Meeting summary and close

Scientific Posters

You can view the posters now as downloadable PDFs or as interactive, page-turning books, these files (which open in a new window) require the latest version of Flash Player to be viewed.

Book 1
Interactive Book or PDF
ORAL PRESENTATIONS
HEPATITIS C VIRUS – DIAGNOSIS (P1–P3)
HEPATITIS C VIRUS – NATURAL HISTORY AND EPIDEMIOLOGY (P5–P7)
HEPATITIS C VIRUS – TREATMENT AND LATE-STAGE CLINICAL TRIALS (P8-P10)

Book 2
Interactive Book or PDF
HEPATITIS C VIRUS – PRACTICAL MANAGEMENT STRATEGIES (P11)
HEPATITIS C VIRUS – TREATMENT MONITORING AND PREDICTORS OF THERAPEUTIC RESPONSE  (P13–P16)
HEPATITIS C VIRUS – DIRECT-ACTING ANTIVIRAL COMBINATIONS (P17-P20)
HEPATITIS C VIRUS – MOLECULAR BIOLOGY AND CHARACTERISATION (P21–P22)

Book 3
Interactive Book or PDF
HEPATITIS C VIRUS – OTHER (P24–P25)
HEPATITIS B VIRUS – DIAGNOSIS AND MONITORING (P28-P29)
HEPATITIS B VIRUS – PRACTICAL MANAGEMENT STRATEGIES (P32)
HEPATITIS B VIRUS – MOLECULAR BIOLOGY AND CHARACTERISATION (P33–P43)
HEPATITIS B VIRUS – OTHER (P44)
HEPATOCELLULAR CARCINOMA (HCC) (P45)
TRANSPLANTATION AND VIRAL HEPATITIS (P47–P48)


Industry sessions (in programme order)

JANSSEN / ACHILLION – PRE-CONGRESS WORKSHOP
12.00-13.00, Thursday 10 September

JANSSEN – INDUSTRY SYMPOSIUM
17.30-19.00, Thursday 10 September

ABBVIE – INDUSTRY SYMPOSIUM
08.30-10.00, Friday 11 September

BRISTOL- MYERS SQUIBB – INDUSTRY SYMPOSIUM
17.30-19.00, Friday 11 September

GILEAD – INDUSTRY SYMPOSIUM
08.30-10.00, Saturday 12 September

Final Programme


You can download the full programme by clicking here or individual sections by clicking the links below.

Back to top